MedPredict Releases New Report Focusing on Rheumatology Pipeline

Share Article

Advisory Board report discusses key development activities in the rheumatology pipeline, perspectives on unmet needs and how different mechanisms are likely to address these, and updates on most promising compounds in development.

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, with a focus on rheumatoid arthritis (RA).

“This report previews how newly launched and pipeline therapeutics are going to fare in an Obamacare world,” according to MedPredict president Jeffrey Berk. “Our panel of peer-recognized thought leaders reflects on the current status of the pipeline for rheumatology therapies, and provides useful insight for decision-makers in this environment.”

To develop this Advisory Board report, entitled “Thought Leader Insight & Analysis: Rheumatology Q2 2010,” MedPredict conducted primary interviews with six U.S.-based and European rheumatology thought leaders. MedPredict has published over 29 research reports in rheumatology and maintains ongoing relationships with experts in North America and Western Europe.

Some of the issues analyzed in this report:

-- Early reactions to Roche/Chugai’s Actemra, recently launched in the U.S. Will its impressive efficacy data outweigh cardiovascular concerns? Where will Actemra be placed in the rheumatologist’s armamentarium?

-- Perceptions of Pfizer’s tasocitinib (CP-690550), which will likely be the first oral DMARD with potency to match biologicals to gain FDA approval. Will it be used ahead of anti-TNF alpha inhibitors?

-- Potential winners and losers under increasing healthcare cost pressures in the U.S. and Europe.

-- Role of diagnostics and biomarkers – how are they being developed in concert with anti-rheumatics?

-- Most interesting new mechanisms for signs & symptoms associated with osteoarthritis.

Companies/Partnerships mentioned in this report include: Abbott, Alder/BMS, Amgen/Pfizer, Array, AstraZeneca, Bristol-Myers Squibb, Centocor/Schering-Plough (Merck), ChemoCentryx/GSK, Genentech/Roche, Genentech/Roche/Chugai, GlaxoSmithKline/Human Genome Sciences, Incyte, Lexicon, Lilly, Merck, Merck Serono, Millennium/Takeda, Novartis, Pfizer, Rigel/AstraZeneca, Stryker, Trubion/Pfizer, UCB.

This report can be purchased by contacting MedPredict.

About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

For more information contact:
Elizabeth Mathews
MedPredict
513.271.1924
liz(at)medpredict(dot)com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elizabeth Mathews
Visit website